Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
CSPC Pharmaceutical Group ( (HK:1093) ) has shared an announcement.
CSPC Innovation Pharmaceutical Co., a subsidiary of CSPC Pharmaceutical Group, has reported its indicative financial results for the year ending December 31, 2024, showing a significant decrease in net profit compared to the previous year. The decline in profits is attributed to the reclassification of non-recurring gains from the acquisition of Megalith Biopharmaceutical, impacting the company’s financial performance and potentially affecting investor sentiment.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a prominent player in the pharmaceutical industry, focusing on the development and manufacturing of innovative and generic drugs. The company operates primarily in the Chinese market and is listed on the Hong Kong Stock Exchange.
YTD Price Performance: -4.92%
Average Trading Volume: 7,366
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.56B
See more insights into 1093 stock on TipRanks’ Stock Analysis page.
